Aurora Therapeutics, cofounded by Nobel Prize–winning scientist Jennifer Doudna, plans to use gene editing and a new FDA ...

If I were to locate the moment AI slop broke through into popular consciousness, I’d pick the video of rabbits bouncing on a ...

Here at MIT Technology Review we’ve been writing about the gene-editing technology CRISPR since 2013, calling it the biggest ...

Scientists have discovered a new CRISPR mechanism with precise activity, expanding the potential applications of the existing ...

The gene therapy success with Baby KJ, along with a new FDA program, have companies more interested in treating rare disease.

Menlo Ventures has made a $16 million bet that the “ baby KJ ” custom CRISPR therapy success story is repeatable. The funding ...

CRISPR Therapeutics AG (CRSP) ended the recent trading session at $53.84, demonstrating a -4.54% change from the preceding ...

Crops increasingly need to thrive in a broader range of conditions, including drought, salinity, and heat. Traditional plant ...

Environmental antimicrobial resistance is turning rivers, soils, and even the air into hidden highways for "superbugs," ...

Corporate presentation at 7:30 AM PST on January 15 in room Elizabethan A at the Westin St. Frances hotel, San Francisco ...

Leveraging modular gene editors and new regulatory pathways, Aurora will develop and commercialize therapies that can be rapidly tailored to many rare variants -- Founded by CRISPR pioneers Jennifer ...

Co-founded by Jennifer Doudna and Fyodor Urnov, the company intends to simultaneously develop many gene editing treatments for rare conditions by using the agency’s “plausible mechanism” pathway.